Abstract
We present the socio-economic consequences of the chronic infantile neurological cutaneous and articular syndrome (CINCA), one of the various forms of the cryopyrin-associated periodic syndrome (CAPS), through the analysis of the 18 years-long story of one patient. We interviewed the patient and his mother and collected clinical documentation to estimate his life-time costs from the perspectives of the healthcare system and society. Total societal and healthcare costs amount to €178,394 and €137,272, respectively. For about 12 years the patient was not correctly diagnosed; health care costs in this period amounted to €81,280, mainly due to hospital care. After the disease was diagnosed, the pattern of costs dramatically changed with a sharp reduction of hospital costs and an increase of costs for medical therapy. This socioeconomic case-study illustrates the categories of costs that may be associated to patients with rare diseases and suggests that prompter diagnosis and adequate therapies may be also beneficial from a socio-economic perspective.
Similar content being viewed by others
Bibliografia
Gattorno M, Federici S, Pelagatti MA, et al. Diagnosis and management of autoinflammatory diseases in childhood. J Clin Immunol 2008; 28 Suppl. 1: S73–83
Koné-Paut I, Marie I, Piram M, T-A Tran. Cryopyrin-associated syndromes-patient quality of life and psychological impact. European Musculoskeletal Review 2009; 4: 60–2
Neven B, Prieur AM, Quartier dit Maire P, Medscape. Cryopyrinopathies: update on pathogenesis and treatment. Nat Clin Pract Rheumatol 2008; 4: 481–9
Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Canakinumab in CAPS Study Group. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360: 2416–25
Koné-Paut I, Lachmann HJ, Kuemmerle-Deschner JB, et al. Improved health-related quality of life in patients with cryopyrin-associated periodic fever syndrome (CAPS) after treatment with canakinumab (ILARIS) — A fully human anti-IL-1 beta monoclonal antibody. Presented at ACR 2009 (17–21 October), Philadelphia, Pennsylvania, USA. Poster 1482
Kuemmerle-Deschner JB, Hoyer J, Hachulla E, et al. Effect of canakinumab (Ilaris, a fully human anti-IL beta monoclonal antibody) on the health-related quality of life (HRQoL) in cryopyrin-associated periodic syndrome (CAPS) patients. Presented at ACR 2009 (17–21 October), Philadelphia, Pennsylvania, USA. Poster 1483
Ministero dell’Economia e delle Finanze, Commissione Tecnica per la Spesa Pubblica. Libro Verde sulla Spesa Pubblica. Roma, settembre 2007. Disponibile a: http://www.mef.gov.it/doc-finanza-pubblica/documenti/18827/28_libro %20verde.pdf
Conferenza delle Reg on e delle Province Autonome. Tariffa unica convenzionale per le prestazioni di assistenza ospedaliera. Regole e tariffe valide per l’anno 2006. Roma, 15 dicembre 2005
Ministero della Sanità. Prestazioni di assistenza specialistica ambulatoriale erogabili nell’ambito del Servizio Sanitario Nazionale e relative tariffe. Decreto Ministeriale del 22 luglio 1996, pubblicato sul Supplemento Ordinario alla Gazzetta Ufficiale n. 216 del 14 settembre 1996
ISTAT. Lavoro e retribuzioni, anni 2005–2006. Roma, 2008
Associazione Italiana di Economia Sanitaria (AIES). Proposta di linee guida per la valutazione economica degli interventi sanitari in Italia. Pharmacoeconomics-Italian Research Articles 2009; 11: 83–93
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fattore, G., Gattorno, M. Analisi socio-economica di lungo periodo di un paziente con una malattia reumatologica rara (CINCA). Pharmacoeconomics-Ital-Res-Articles 12, 157–165 (2010). https://doi.org/10.1007/BF03320673
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03320673